Carib A. Oquendo

Array ( [id] => 16452625 [patent_doc_number] => 20200362051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => MOLECULES THAT BIND TO CD137 AND PSMA [patent_app_type] => utility [patent_app_number] => 16/763063 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406867 [patent_doc_number] => 20190169277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => MODIFIED ANTI-TENASCIN ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/186418 [patent_app_country] => US [patent_app_date] => 2018-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36612 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16186418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15540849 [patent_doc_number] => 10570190 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same [patent_app_type] => utility [patent_app_number] => 16/175002 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 18 [patent_no_of_words] => 12580 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16175002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15540849 [patent_doc_number] => 10570190 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same [patent_app_type] => utility [patent_app_number] => 16/175002 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 18 [patent_no_of_words] => 12580 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16175002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929973 [patent_doc_number] => 20190300624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => HER3 ANTIGEN-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/170370 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14501361 [patent_doc_number] => 20190194335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => ANTIBODIES SPECIFIC FOR EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND THEIR USES [patent_app_type] => utility [patent_app_number] => 16/163243 [patent_app_country] => US [patent_app_date] => 2018-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16163243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17890763 [patent_doc_number] => 11453716 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Single domain serum albumin binding protein [patent_app_type] => utility [patent_app_number] => 16/161986 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14901 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16161986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437146 [patent_doc_number] => 20200354472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/754677 [patent_app_country] => US [patent_app_date] => 2018-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16754677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14342247 [patent_doc_number] => 20190153096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => CD3/CD33 BISPECIFIC BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/140576 [patent_app_country] => US [patent_app_date] => 2018-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16140576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15422611 [patent_doc_number] => 10544219 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => TIGIT-binding agents and uses thereof [patent_app_type] => utility [patent_app_number] => 16/138418 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 56 [patent_no_of_words] => 67049 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16138418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328418 [patent_doc_number] => 20200299384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => NOVEL ANTI-CD3EPSILON ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/649149 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16252265 [patent_doc_number] => 20200261639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNA [patent_app_type] => utility [patent_app_number] => 16/648045 [patent_app_country] => US [patent_app_date] => 2018-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13957935 [patent_doc_number] => 20190055311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => Agents for Treatment of Claudin Expressing Cancer Diseases [patent_app_type] => utility [patent_app_number] => 16/117197 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16117197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17633916 [patent_doc_number] => 11344621 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => Interleukin-13 binding proteins [patent_app_type] => utility [patent_app_number] => 16/113027 [patent_app_country] => US [patent_app_date] => 2018-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44597 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16113027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733209 [patent_doc_number] => 20180371072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS [patent_app_type] => utility [patent_app_number] => 16/112304 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45343 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16112304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14158783 [patent_doc_number] => 20190106494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis [patent_app_type] => utility [patent_app_number] => 16/111158 [patent_app_country] => US [patent_app_date] => 2018-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14019027 [patent_doc_number] => 20190071507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/055947 [patent_app_country] => US [patent_app_date] => 2018-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16055947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17177371 [patent_doc_number] => 11154600 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Use of anti-CD47 agents to enhance immunization [patent_app_type] => utility [patent_app_number] => 16/048862 [patent_app_country] => US [patent_app_date] => 2018-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 30 [patent_no_of_words] => 15073 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16048862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15816573 [patent_doc_number] => 10633452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-28 [patent_title] => Anti-cancer antibodies with reduced complement fixation [patent_app_type] => utility [patent_app_number] => 16/026846 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 5235 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14375279 [patent_doc_number] => 20190161552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => ANTI-BCMA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/026242 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14891 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026242 [rel_patent_id] =>[rel_patent_doc_number] =>)